HomeInsightsResults

Aurobindo Pharma Ltd Quarterly Result

Aurobindo Pharma Ltd Quarterly Result

stocks purchased

₹ 3.9 Cr

Volume Transacted

(Dec 20, 2024)

stocks purchased

31.6 K

Stocks Traded

(Dec 20, 2024)

Last Updated on: Dec 23, 2024

Image

Aurobindo Pharma Ltd

NSE: AUROPHARMA

Net Profit

₹ 816.95

Last updated on: Dec 23, 2024

Key Highlights

  • The revenue of Aurobindo Pharma Ltd for the Sep '24 is ₹ 7932 crore as compare to the Jun '24 revenue of ₹ 7787 crore. This represent the growth of 1.8544022%.
  • The ebitda of Aurobindo Pharma Ltd for the Sep '24 is ₹ 1702 crore as compare to the Jun '24 ebitda of ₹ 1839 crore. This represent the decline of -7.431314%.
  • The net profit of Aurobindo Pharma Ltd for the Sep '24 is ₹ 816.95 crore as compare to the Jun '24 net profit of ₹ 918.22 crore. This represent the decline of -11.028943%.

Results Analysis

Market Price of Aurobindo Pharma Ltd

1M

1Y

3Y

5Y

Monitoring Aurobindo Pharma Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
20 Dec 20241240.7
19 Dec 20241255.4
18 Dec 20241247.85
17 Dec 20241213.45
16 Dec 20241245
13 Dec 20241207.95
12 Dec 20241215.15
11 Dec 20241225.7
10 Dec 20241238.05
09 Dec 20241239.4

Historical Revenue of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical EBITDA of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical Net Profit of Aurobindo Pharma Ltd

No data available

* All values are in crore

Aurobindo Pharma Ltd News Hub

News

Auro Pharma gets UK MHRA nod for cancer drug

Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (4...

Read more

21 Dec 2024 15:20

News

Auro Pharma's Telangana unit gets 2 USFDA observations

The United States Food and Drug Administration (US FDA) inspected Unit-V, an API manufactu...

Read more

18 Dec 2024 11:17

News

Apitoria Pharma's Unit V completes USFDA inspection

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) in...

Read more

17 Dec 2024 19:55

News

Aurobindo Pharma arm receives positive opinion from EMA for Zefylti

The CHMP has recommended the granting of marketing authorization for Zefylti, which is int...

Read more

14 Dec 2024 16:18

News

Aurobindo Pharma Ltd drops for fifth straight session

Aurobindo Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 1...

Read more

13 Dec 2024 13:35

News

CuraTeQ Biologics received recommendation of a marketing authorisation for Zefylti

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma,  announced that the Comm...

Read more

13 Dec 2024 18:31

Document

Annual Reports

Annual Report 2024

dropdown
download

Credit Ratings

Credit Report 2024

dropdown
download

Concalls

June 2023

TranscriptPPT

June 2022

TranscriptPPT

Aug 2021

PPT

June 2021

TranscriptPPT

June 2020

TranscriptPPT

Jan 2020

PPT

FAQs for Quarterly Results of Aurobindo Pharma Ltd

What key financial metrics are included in Aurobindo Pharma Ltd's quarterly results?

Key financial metrics in Aurobindo Pharma Ltd's quarterly results typically include revenue, net profit, earnings per share (EPS), and operating margins. Other metrics might include cash flow, operating expenses, and client metrics.

When does Aurobindo Pharma Ltd announce its quarterly results?

Aurobindo Pharma Ltd usually announces its quarterly results around mid-July for Q1, mid-October for Q2, mid-January for Q3, and mid-April for Q4, aligning with the end of each fiscal quarter. However, different finance companies have their respective schedules for announcing their quarterly results.

How does Aurobindo Pharma Ltd's quarterly performance impact its stock price?

Aurobindo Pharma Ltd's quarterly performance can lead to stock price volatility, with strong results often driving the price up, while disappointing results can cause it to drop. Investor sentiment and market expectations also play significant roles.

What is the impact of Aurobindo Pharma Ltd's quarterly results on dividends?

The impact of Aurobindo Pharma Ltd's quarterly results on dividends can influence dividend decisions, with strong performance potentially leading to increased or special dividends, while weaker results might result in stable or reduced dividends.

Are there any special announcements usually made during Aurobindo Pharma Ltd's quarterly results?

Yes, Aurobindo Pharma Ltd often makes special announcements during its quarterly results, including strategic updates, key client wins, and major contract renewals. They might also guide future performance and share insights on industry trends. These updates are typically highlighted in their press release. However, special announcements made during quarterly results may vary from company to company.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions